Advertisement

Pharmaceutical company Alkermes Inc. (Nasdaq: ALKS) reported this morning that Nasdaq has halted trading of Alkermes’ common stock because of an expedited review by a U.S. Food and Drug Administration.

In a press release, Waltham-based Alkermes said the Psychopharmacologic Drugs Advisory Committee appointed by the FDA meets today to review the company’s supplemental New Drug Application (sDNA) for Vivitrol (naltrexone for extended-release injectable suspension) for opioid dependence.

SOURCE

Advertisement
Advertisement